Absorption enhancers for nasal drug delivery
This paper describes the basic concepts for the transmucosal delivery of drugs, and in particular the use of the nasal route for delivery of challenging drugs such as polar low-molecular-weight drugs and peptides and proteins. Strategies for the exploitation of absorption enhancers for the improveme...
Gespeichert in:
| Veröffentlicht in: | Clinical pharmacokinetics 2003-01, Vol.42 (13), p.1107-1128 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1128 |
|---|---|
| container_issue | 13 |
| container_start_page | 1107 |
| container_title | Clinical pharmacokinetics |
| container_volume | 42 |
| creator | DAVIS, Stanley S ILIUM, Lisbeth |
| description | This paper describes the basic concepts for the transmucosal delivery of drugs, and in particular the use of the nasal route for delivery of challenging drugs such as polar low-molecular-weight drugs and peptides and proteins. Strategies for the exploitation of absorption enhancers for the improvement of nasal delivery are discussed, including consideration of mechanisms of action and the correlation between toxic effect and absorption enhancement. Selected enhancer systems, such as cyclodextrins, phospholipids, bioadhesive powder systems and chitosan, are discussed in detail. Examples of the use of these enhancers in preclinical and clinical studies are given. Methods for assessing irritancy and damage to the nasal membrane from the use of absorption enhancers are also described. Finally, the mucosal use of absorption enhancers (chitosan) for the improved nasal delivery of vaccines is reported with reference to recent phase I/II clinical studies. |
| doi_str_mv | 10.2165/00003088-200342130-00003 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A199914738</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A199914738</galeid><sourcerecordid>A199914738</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-42c2541d2aaa1af7de95ba4eeb0d17d94569e6d3f9c8ae868e57c4929bda37bb3</originalsourceid><addsrcrecordid>eNptkMtKAzEUhoMotlZfQQbEnVNznSTLUrxBwY2uhzO51Mh0piSt0Lc3OtUieM7iwM_3ncWPUEHwlJJK3OI8DCtV0nw5JQyX39ERGhMidUk0rY7RGDNCS6ErNkJnKb1nQmXhFI0IF4xIysboZtakPq43oe8K171BZ1xMhe9j0UGCtrBxuyysa8OHi7tzdOKhTe5ifyfo9f7uZf5YLp4fnuazRWm45JuSU0MFJ5YCAAEvrdOiAe5cgy2RVnNRaVdZ5rVR4FSlnJCGa6obC0w2DZugq-HvElpXh873mwhmFZKpZ0RrTbhkKlPTf6i81q2C6TvnQ87_CGoQTOxTis7X6xhWEHc1wfVXr_VPr_Vvr0OU1ctBXW-blbMHcV9kBq73ACQDrY-5yZAOnKBUMSzZJwPFfiI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Absorption enhancers for nasal drug delivery</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>DAVIS, Stanley S ; ILIUM, Lisbeth</creator><creatorcontrib>DAVIS, Stanley S ; ILIUM, Lisbeth</creatorcontrib><description>This paper describes the basic concepts for the transmucosal delivery of drugs, and in particular the use of the nasal route for delivery of challenging drugs such as polar low-molecular-weight drugs and peptides and proteins. Strategies for the exploitation of absorption enhancers for the improvement of nasal delivery are discussed, including consideration of mechanisms of action and the correlation between toxic effect and absorption enhancement. Selected enhancer systems, such as cyclodextrins, phospholipids, bioadhesive powder systems and chitosan, are discussed in detail. Examples of the use of these enhancers in preclinical and clinical studies are given. Methods for assessing irritancy and damage to the nasal membrane from the use of absorption enhancers are also described. Finally, the mucosal use of absorption enhancers (chitosan) for the improved nasal delivery of vaccines is reported with reference to recent phase I/II clinical studies.</description><identifier>ISSN: 0312-5963</identifier><identifier>EISSN: 1179-1926</identifier><identifier>DOI: 10.2165/00003088-200342130-00003</identifier><identifier>PMID: 14531723</identifier><identifier>CODEN: CPKNDH</identifier><language>eng</language><publisher>Auckland: Adis international</publisher><subject>Absorption ; Adjuvants, Pharmaceutic - adverse effects ; Adjuvants, Pharmaceutic - chemistry ; Administration, Intranasal ; Animals ; Biological and medical sciences ; Clinical Trials as Topic ; Drug Design ; Drug-Related Side Effects and Adverse Reactions ; General pharmacology ; Humans ; Medical sciences ; Peptides - administration & dosage ; Pharmaceutical Preparations - administration & dosage ; Pharmaceutical Preparations - chemistry ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Proteins - administration & dosage ; Vaccines - administration & dosage ; Vaccines - chemistry</subject><ispartof>Clinical pharmacokinetics, 2003-01, Vol.42 (13), p.1107-1128</ispartof><rights>2004 INIST-CNRS</rights><rights>COPYRIGHT 2003 Wolters Kluwer Health, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-42c2541d2aaa1af7de95ba4eeb0d17d94569e6d3f9c8ae868e57c4929bda37bb3</citedby><cites>FETCH-LOGICAL-c474t-42c2541d2aaa1af7de95ba4eeb0d17d94569e6d3f9c8ae868e57c4929bda37bb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15228307$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14531723$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DAVIS, Stanley S</creatorcontrib><creatorcontrib>ILIUM, Lisbeth</creatorcontrib><title>Absorption enhancers for nasal drug delivery</title><title>Clinical pharmacokinetics</title><addtitle>Clin Pharmacokinet</addtitle><description>This paper describes the basic concepts for the transmucosal delivery of drugs, and in particular the use of the nasal route for delivery of challenging drugs such as polar low-molecular-weight drugs and peptides and proteins. Strategies for the exploitation of absorption enhancers for the improvement of nasal delivery are discussed, including consideration of mechanisms of action and the correlation between toxic effect and absorption enhancement. Selected enhancer systems, such as cyclodextrins, phospholipids, bioadhesive powder systems and chitosan, are discussed in detail. Examples of the use of these enhancers in preclinical and clinical studies are given. Methods for assessing irritancy and damage to the nasal membrane from the use of absorption enhancers are also described. Finally, the mucosal use of absorption enhancers (chitosan) for the improved nasal delivery of vaccines is reported with reference to recent phase I/II clinical studies.</description><subject>Absorption</subject><subject>Adjuvants, Pharmaceutic - adverse effects</subject><subject>Adjuvants, Pharmaceutic - chemistry</subject><subject>Administration, Intranasal</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Clinical Trials as Topic</subject><subject>Drug Design</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Peptides - administration & dosage</subject><subject>Pharmaceutical Preparations - administration & dosage</subject><subject>Pharmaceutical Preparations - chemistry</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Proteins - administration & dosage</subject><subject>Vaccines - administration & dosage</subject><subject>Vaccines - chemistry</subject><issn>0312-5963</issn><issn>1179-1926</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkMtKAzEUhoMotlZfQQbEnVNznSTLUrxBwY2uhzO51Mh0piSt0Lc3OtUieM7iwM_3ncWPUEHwlJJK3OI8DCtV0nw5JQyX39ERGhMidUk0rY7RGDNCS6ErNkJnKb1nQmXhFI0IF4xIysboZtakPq43oe8K171BZ1xMhe9j0UGCtrBxuyysa8OHi7tzdOKhTe5ifyfo9f7uZf5YLp4fnuazRWm45JuSU0MFJ5YCAAEvrdOiAe5cgy2RVnNRaVdZ5rVR4FSlnJCGa6obC0w2DZugq-HvElpXh873mwhmFZKpZ0RrTbhkKlPTf6i81q2C6TvnQ87_CGoQTOxTis7X6xhWEHc1wfVXr_VPr_Vvr0OU1ctBXW-blbMHcV9kBq73ACQDrY-5yZAOnKBUMSzZJwPFfiI</recordid><startdate>20030101</startdate><enddate>20030101</enddate><creator>DAVIS, Stanley S</creator><creator>ILIUM, Lisbeth</creator><general>Adis international</general><general>Wolters Kluwer Health, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20030101</creationdate><title>Absorption enhancers for nasal drug delivery</title><author>DAVIS, Stanley S ; ILIUM, Lisbeth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-42c2541d2aaa1af7de95ba4eeb0d17d94569e6d3f9c8ae868e57c4929bda37bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Absorption</topic><topic>Adjuvants, Pharmaceutic - adverse effects</topic><topic>Adjuvants, Pharmaceutic - chemistry</topic><topic>Administration, Intranasal</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Clinical Trials as Topic</topic><topic>Drug Design</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Peptides - administration & dosage</topic><topic>Pharmaceutical Preparations - administration & dosage</topic><topic>Pharmaceutical Preparations - chemistry</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Proteins - administration & dosage</topic><topic>Vaccines - administration & dosage</topic><topic>Vaccines - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DAVIS, Stanley S</creatorcontrib><creatorcontrib>ILIUM, Lisbeth</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Clinical pharmacokinetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DAVIS, Stanley S</au><au>ILIUM, Lisbeth</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Absorption enhancers for nasal drug delivery</atitle><jtitle>Clinical pharmacokinetics</jtitle><addtitle>Clin Pharmacokinet</addtitle><date>2003-01-01</date><risdate>2003</risdate><volume>42</volume><issue>13</issue><spage>1107</spage><epage>1128</epage><pages>1107-1128</pages><issn>0312-5963</issn><eissn>1179-1926</eissn><coden>CPKNDH</coden><abstract>This paper describes the basic concepts for the transmucosal delivery of drugs, and in particular the use of the nasal route for delivery of challenging drugs such as polar low-molecular-weight drugs and peptides and proteins. Strategies for the exploitation of absorption enhancers for the improvement of nasal delivery are discussed, including consideration of mechanisms of action and the correlation between toxic effect and absorption enhancement. Selected enhancer systems, such as cyclodextrins, phospholipids, bioadhesive powder systems and chitosan, are discussed in detail. Examples of the use of these enhancers in preclinical and clinical studies are given. Methods for assessing irritancy and damage to the nasal membrane from the use of absorption enhancers are also described. Finally, the mucosal use of absorption enhancers (chitosan) for the improved nasal delivery of vaccines is reported with reference to recent phase I/II clinical studies.</abstract><cop>Auckland</cop><pub>Adis international</pub><pmid>14531723</pmid><doi>10.2165/00003088-200342130-00003</doi><tpages>22</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0312-5963 |
| ispartof | Clinical pharmacokinetics, 2003-01, Vol.42 (13), p.1107-1128 |
| issn | 0312-5963 1179-1926 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A199914738 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Absorption Adjuvants, Pharmaceutic - adverse effects Adjuvants, Pharmaceutic - chemistry Administration, Intranasal Animals Biological and medical sciences Clinical Trials as Topic Drug Design Drug-Related Side Effects and Adverse Reactions General pharmacology Humans Medical sciences Peptides - administration & dosage Pharmaceutical Preparations - administration & dosage Pharmaceutical Preparations - chemistry Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Proteins - administration & dosage Vaccines - administration & dosage Vaccines - chemistry |
| title | Absorption enhancers for nasal drug delivery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T04%3A13%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Absorption%20enhancers%20for%20nasal%20drug%20delivery&rft.jtitle=Clinical%20pharmacokinetics&rft.au=DAVIS,%20Stanley%20S&rft.date=2003-01-01&rft.volume=42&rft.issue=13&rft.spage=1107&rft.epage=1128&rft.pages=1107-1128&rft.issn=0312-5963&rft.eissn=1179-1926&rft.coden=CPKNDH&rft_id=info:doi/10.2165/00003088-200342130-00003&rft_dat=%3Cgale_cross%3EA199914738%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/14531723&rft_galeid=A199914738&rfr_iscdi=true |